Trial Profile
An Observational Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms RELIVE
- Sponsors Abbott Laboratories; AbbVie
- 10 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Mar 2013 Planned end date changed from 1 May 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov
- 19 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.